EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial

Johan Bröjer iD, Siv Hanche-Olsen iD, Constanze Fintl iD, Elin Svonni iD, Ingunn Risnes Hellings iD, Cecilia Müller iD, Sanna Lindåse iD

Journal of Veterinary Internal Medicine · 2026

DOI: 10.1093/jvimsj/aalag107 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Veterinary Internal Medicine, 2026. Verfasst von Johan Bröjer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden. Hauptthemen laut MEDLINE: Canagliflozin, Horse Diseases, Hyperinsulinism, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish-Norwegian Foundation for Equine Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are promising drugs for treatment of hyperinsulinemia in insulin-dysregulated (ID) horses. Hypothesis/Objectives Compare short-term effects of the SGLT2 inhibitor canagliflozin versus placebo on glucose and insulin responses during an oral sugar test (OST) and a forage-based feed challenge test (FCT), and to assess adverse effects. Animals Forty-two privately owned severely ID horses.

Methods

Multi-center, randomized, double-blind, placebo-controlled, parallel-group study. Horses were allocated (1:1:1) to receive canagliflozin (0.6 or 1.2 mg/kg PO q24h) or placebo. The study included a 5-day baseline evaluation, a 4-week at-home double-blind treatment period, and a 5-day follow-up evaluation. During each clinical visit, an OST (day 3) and FCT (day 4) were performed to characterize glucose and insulin responses. Adverse effects were recorded. Data are presented as geometric least squares mean (95% CI).

Results

Peak insulin concentrations (μIU/mL) during the OST and the FCT were lower after treatment with canagliflozin 0.6 and 1.2 mg/kg compared with placebo (P ≤ .01); OST: 122.0 (96.6-154.0) and 108.6 (85.6-137.8) vs 288.7 (227.1-366.9) and FCT: 78.3 (37.6-162.9) and 54.2 (25.7-114.5) vs 140.3 (68.5-287.3). Canagliflozin caused a dose-dependent increase in triglyceride concentrations (P ≤ .01). Post-treatment triglyceride concentrations were 0.5 (0.4-0.8), 1.3 (0.9-2.0), and 2.9 (1.9-4.4) mmol/L for placebo, 0.6 mg/kg, and 1.2 mg/kg groups, respectively. Conclusions and clinical importance Canagliflozin effectively decreases hyperinsulinemia in ID horses but induces a dose-dependent increase in triglyceride concentrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinHorse DiseasesHyperinsulinismHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 InhibitorsAnimalsFemaleMaleBlood GlucoseDouble-Blind MethodHorses

Stichwörter der Autor:innen

SGLT2 inhibitorequineequine metabolic syndromehyperinsulinemiasodium-glucose cotransporter 2 inhibitor

Substanzen

Blood GlucoseCanagliflozinHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.
  • Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences, 1432 Ås, Norway.
  • Department of Applied Animal Science and Welfare, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.

ORCID-Profile: Johan Bröjer, Siv Hanche-Olsen, Constanze Fintl, Elin Svonni, Ingunn Risnes Hellings, Cecilia Müller, Sanna Lindåse

Förderung

  • Swedish-Norwegian Foundation for Equine Research

Zitieren

APA

Bröjer, J., Hanche-Olsen, S., Fintl, C., Svonni, E., Hellings, I. R., Müller, C., & Lindåse, S. (2026). Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial. Journal of Veterinary Internal Medicine. https://doi.org/10.1093/jvimsj/aalag107

Vancouver

Bröjer J, Hanche-Olsen S, Fintl C, Svonni E, Hellings IR, Müller C, et al. Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial. Journal of Veterinary Internal Medicine. 2026. doi:10.1093/jvimsj/aalag107

BibTeX
@article{Brjer2026,
  author = {Bröjer, Johan and Hanche-Olsen, Siv and Fintl, Constanze and Svonni, Elin and Hellings, Ingunn Risnes and Müller, Cecilia and Lindåse, Sanna},
  title = {Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  doi = {10.1093/jvimsj/aalag107}
}
Kostenlos starten →